Search - tctmd.com

Displaying 61 - 80 of 106

Sort: Relevancy | Date

News Daily News

Myocardial Injury Seen in Over One-Third of Hospitalized COVID-19 Patients

Michael O'Riordan

June 10, 2020

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Daily News

Latest Kawasaki Series Offers Clues to COVID-19 in Kids as Debate Persists

Shelley Wood

May 14, 2020

News Features

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Shelley Wood

April 21, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

News Daily News

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Michael O'Riordan

December 20, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

Yael L. Maxwell

November 12, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Todd Neale

August 26, 2018

News Daily News

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Yael L. Maxwell

August 03, 2018

Advertisement

Myocardial Injury Seen in Over One-Third of Hospitalized COVID-19 Patients

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

Latest Kawasaki Series Offers Clues to COVID-19 in Kids as Debate Persists

Obesity and COVID-19: Theories and Blame Fill the Scientific Void

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

CvLPRIT: Long-term Reduction in Death/MI With Complete Revascularization

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

TCTMD’s Top 10 Most Popular Stories for February 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Cell Therapy No Help for Cardiac Recovery in HF Patients With LVADs

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content